Quest Diagnostics二季度业绩超预期并上调2026年收入和利润指引

Quest Diagnostics (DGX.N) on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped ​the company beat second-quarter estimates.

Shares of the New ‌Jersey-based company rose about 5% in premarket trading following the results.

Here are the details:

Demand for the company's diagnostic testing ​services was strong across its physician, hospital and ​consumer channels, Quest said.

The results were "well above what ⁠was widely expected," Barclays analysts said.

Industry peer Labcorp (LH.N) ​also raised its annual revenue and profit forecasts last quarter, ​after posting quarterly results above expectations as demand for diagnostic testing remained steady.

Quest Diagnostics reported second-quarter revenue of $3.04 billion, topping analysts' ​average estimate of $2.97 billion, according to data compiled by ​LSEG.

Adjusted profit was $3.12 per share, above expectations of $2.83 per share.

Revenue from ‌diagnostic ⁠information services, Quest's largest segment, increased 10.3% to $2.98 billion from a year ago, helped by a 13.1% increase in requisition volumes, including 13.0% organic volume growth.

Quest ​also reported double-digit ​growth in ⁠advanced diagnostics businesses, including Alzheimer's disease blood tests, advanced cardiometabolic tests and liver ​fibrosis testing.

The company expects 2026 revenue of $11.95 ​billion to $12.05 ⁠billion, above its prior forecast of $11.78 billion to $11.90 billion and analysts' estimate of $11.85 billion.

Quest expects adjusted profit of $11.05 ⁠to $11.25 ​per share in 2026, compared ​with its previous forecast of $10.63 to $10.83 per share. Analysts expect $10.76 per share.